Retour

Tilray Brands, Inc.

Qualité des données : 100%

TLRY

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic

6,94 €

▲ 0,28 € (4,20%)

Cap. Boursière : 702,66M

Fourchette du Jour

6,76 € 7,08 €

Fourchette 52 Semaines

3,50 € 23,20 €

Volume

2 576 772

Moyenne 50J / 200J

7,86 € / 9,48 €

Clôture Précédente

6,66 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique	Action	Médiane du Secteur
P/E	-0,2	0,2
P/B	0,3	3,0
ROE %	-88,7	3,6
Net Margin %	-266,3	3,8
Rev Growth 5Y %	16,1	9,9
D/E	0,2	0,2

Objectif de Cours des Analystes

Hold

10,00 € +44.1%

BPA Prévisionnel

-0,48 €

CA Est.

864,39M

Estimations de Bénéfices

Période	BPA Est.	CA Est.	Analystes
FY2030	0,36 € 0,35 € – 0,38 €	1,12B	1
FY2029	0,22 € 0,21 € – 0,23 €	1,08B	1
FY2028	-0,05 € -0,05 € – -0,05 €	983,83M	1

Earnings Surprises

Last 8 quarters

Quarter	Est. EPS	Actual EPS	Surprise
2026-01-08	-0,21 €	-0,41 €	-91,9%
2025-10-09	-0,27 €	0,00 €	+98,4%
2025-07-28	-0,03 €	0,02 €	+166,7%
2025-04-08	-0,04 €	-0,10 €	-150,0%
2025-01-10	-0,04 €	-0,10 €	-150,0%
2024-10-10	-0,04 €	-0,04 €	-11,1%
2024-07-29	-0,02 €	-0,04 €	-81,8%
2024-04-09	-0,05 €	-0,12 €	-140,0%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue grew 16,13% annually over 5 years — strong growth

Debt/Equity of 0,22 — conservative balance sheet

Negative free cash flow of -174,98M

Revenue growth is decelerating — 1Y growth trails 5Y average by 11,29%

Capital efficient — spends only 4,01% of revenue on capex

Croissance

Revenue Growth (5Y)

16,13%

Revenue (1Y)4,84%

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Qualité

Return on Equity

-88,71%

ROIC-93,03%

Net Margin-266,25%

Op. Margin-277,93%

Sécurité

Debt / Equity

0,22

Current Ratio2,46

Interest Coverage-55,23

Valorisation

P/E Ratio

-0,23

Forward P/EN/A

P/B Ratio0,34

EV/EBITDAN/A

Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	4,84%	Revenue Growth (3Y)	15,51%
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	16,13%	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	1,13B	Net Income (TTM)	-3,00B
ROE	-88,71%	ROA	-103,31%
Gross Margin	29,29%	Operating Margin	-277,93%
Net Margin	-266,25%	Free Cash Flow (TTM)	-174,98M
ROIC	-93,03%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0,22	Current Ratio	2,46
Interest Coverage	-55,23
Dividends
Dividend Yield	0,00%	Payout Ratio	0,00%
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-0,23	Forward P/E	N/A
P/B Ratio	0,34	P/S Ratio	0,62
PEG Ratio	0,00	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	0,81	Fwd Earnings Yield	N/A
FCF Yield	-24,90%
Market Cap	702,66M	Enterprise Value	849,58M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1,13B	1,07B	844,72M	792,12M	619,67M
Net Income	-3,00B	-333,80M	-1,96B	-601,05M	-443,75M
EPS (Diluted)	-33,80	-4,50	-31,70	-11,30	-15,10
Gross Profit	330,11M	304,33M	197,95M	147,26M	148,77M
Operating Income	-3,13B	-238,10M	-1,84B	-769,46M	-159,63M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	2,90B	5,91B	5,92B	6,87B	6,03B
Total Liabilities	860,49M	1,22B	1,44B	1,27B	1,56B
Shareholders' Equity	2,07B	4,69B	4,47B	5,55B	4,46B
Total Debt	451,09M	527,75M	794,89M	786,36M	938,66M
Cash & Equivalents	304,17M	311,13M	278,33M	524,29M	488,47M
Current Assets	944,93M	923,43M	1,04B	1,01B	883,61M
Current Liabilities	384,63M	407,64M	583,21M	353,39M	401,24M